Wednesday - February 18, 2026
Exdensur Approved by the European Commission for Severe Asthma With Type 2 Inflammation and Chronic Rhinosinusitis With Nasal Polyps
February 18, 2026
LONDON, England, Feb. 18 -- GSK (formerly GlaxoSmithKline), a biopharmaceutical company, issued the following news release on Feb. 17, 2026:

* * *

Exdensur (depemokimab) approved by the European Commission for severe asthma with type 2 inflammation and chronic rhinosinusitis with nasal polyps

* Exdensur is the first and only ultra-long-acting biologic in the EU to treat respiratory diseases

* Approval based on four phase III trials with statist . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products